Growing emphasis on early cancer detection is driving demand for molecular and genomic diagnostic tools across breast, cervical, colorectal, prostate, lung, and liver cancers. Experts highlight molecular biomarker testing, HPV DNA testing, and genomic risk stratification as key enablers of preventive, risk-based screening—an evolving diagnostic landscape central to Molbio’s molecular testing focus.